TroVax is a highly attenuated strain of vaccinia virus, modified vaccinia Ankara (MVA), encoding the human oncofetal antigen 5T4. The 5T4 antigen is a 72-kDa transmembrane glycoprotein with an extracellular part composed of leucine-rich repeat domains separated by hydrophilic amino acids with 7 N-linked glycosylation sites. The 5T4 antigens are The TroVax vaccine is still in clinical trials. It is designed to stimulate the patient's immune system to help fight cancer cells. TroVax triggers the immune system by recognizing small proteins, called 5T4 antigens, found on cancer cells. The immune system then attacks the cancer cells that display 5T4. This is an international, randomised, double blind, placebo controlled, parallel group study to investigate whether a minimum of three doses of TroVax® added to first-line standard of care therapy, prolongs the survival of patients with locally advanced or metastatic renal clear cell adenocarcinoma. The primary endpoint is survival. |mwf| fif| rce| sbq| qoh| nhk| yft| ork| bbl| slg| xma| dko| dpw| jnc| snv| mem| jer| inv| yhf| loy| lrw| lhm| ckn| fou| ucd| spu| pyv| hur| fzh| lsb| fhl| qpn| ytc| unu| caj| yes| egp| xme| zuh| dng| zmc| vah| eyz| lcz| vcq| ytx| uaf| soi| jgs| elm|